Targeting regenerative exosomes to myocardial infarction using cardiac homing peptide

Theranostics

Volumn 8, Issue 7, 2018, Pages 1869-1878

  Vandergriff, Adam ^a   Huang, Ke ^a   Shen, Deliang ^b   Hu, Shiqi ^a   Hensley, Michael Taylor ^a   Caranasos, Thomas G ^c   Qian, Li ^c   Cheng, Ke ^a  

^a NORTH CAROLINA STATE UNIVERSITY   (United States)

^b THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIVERSITY   (China)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Cardiac regeneration; Exosomes; Heart disease; Myocardial infarction; Targeting

Indexed keywords

CARDIAC HOMING PEPTIDE; CARDIOVASCULAR AGENT; DIOLEOYLPHOSPHATIDYLETHANOLAMINE; N HYDROXYSUCCINIMIDE; UNCLASSIFIED DRUG; BIOLOGICAL PRODUCT; PEPTIDE;

ANGIOGENESIS; ANIMAL CELL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CARDIAC MUSCLE CELL; CELL GROWTH; CELL PROLIFERATION; CELL REGENERATION; CELL SURVIVAL; CELL TRANSPORT; CELL VIABILITY; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG RESPONSE; ECHOCARDIOGRAPHY; EX VIVO STUDY; EXOSOME; FEMALE; FLUORESCENCE MICROSCOPY; H9C2(2-1) CELL LINE; HEART FUNCTION; HEART INFARCTION; HEART INFARCTION SIZE; HEART MUSCLE FIBROSIS; IN VITRO STUDY; NEWBORN; NONHUMAN; RAT; REPERFUSION INJURY; RETENTION TIME; ANIMAL; BIOLOGICAL THERAPY; DISEASE MODEL; INTRAVENOUS DRUG ADMINISTRATION; MOLECULARLY TARGETED THERAPY; PHYSIOLOGY; PROCEDURES; TREATMENT OUTCOME;

ADMINISTRATION, INTRAVENOUS; ANIMALS; BIOLOGICAL PRODUCTS; BIOLOGICAL THERAPY; CELL SURVIVAL; DISEASE MODELS, ANIMAL; ECHOCARDIOGRAPHY; EXOSOMES; MOLECULAR TARGETED THERAPY; MYOCARDIAL INFARCTION; MYOCYTES, CARDIAC; PEPTIDES; RATS; TREATMENT OUTCOME;

EID: 85042141748     PISSN: None     EISSN: 18387640     Source Type: Journal    
DOI: 10.7150/thno.20524     Document Type: Article

References (79)

1. Bergmann O, Bhardwaj RD, Bernard S, Zdunek S, Barnabé-Heider F, Walsh S, Zupicich J, Alkass K, Buchholz BA, Druid H, Jovinge S, Frisén J. Evidence for Cardiomyocyte Renewal in Humans. Science. 2009; 324:98-102.
2. Houtgraaf JH, Den Dekker WK, Van Dalen BM, Springeling T, De Jong R, Van Geuns RJ, Geleijnse ML, Fernandez-Aviles F, Zijlsta F, Serruys PW, Duckers HJ. First experience in humans using adipose tissue-derived regenerative cells in the treatment of patients with ST-segment elevation myocardial infarction. J Am Coll Cardiol. 2012; 59:539-540.
3. Bartunek J, Behfar A, Dolatabadi D, Vanderheyden M, Ostojic M, Dens J, El Nakadi B, Banovic M, Beleslin B, Vrolix M, Legrand V, Vrints C, Vanoverschelde JL, Crespo-Diaz R, Homsy C, et al. Cardiopoietic stem cell therapy in heart failure: The C-CURE (cardiopoietic stem cell therapy in heart failURE) multicenter randomized trial with lineage-specified biologics. J Am Coll Cardiol. 2013; 61:2329-2338.
4. Makkar RR, Smith RR, Cheng K, Malliaras K, Thomson LEJ, Berman D, Czer LSC, Marbán L, Mendizabal A, Johnston P V, Russell SD, Schuleri KH, Lardo AC, Gerstenblith G, Marbán E. Intracoronary cardiosphere-derived cells for heart regeneration after myocardial infarction (CADUCEUS): a prospective, randomised phase 1 trial. Lancet. 2012; 379:895-904.
5. Bolli R, Chugh AR, D'Amario D, Loughran JH, Stoddard MF, Ikram S, Beache GM, Wagner SG, Leri A, Hosoda T, Sanada F, Elmore JB, Goichberg P, Cappetta D, Solankhi NK, et al. Cardiac stem cells in patients with ischaemic cardiomyopathy (SCIPIO): Initial results of a randomised phase 1 trial. Lancet. 2011; 378:1847-1857.
6. Yau TM, Kim C, Ng D, Li G, Zhang Y, Weisel RD, Li RK. Increasing transplanted cell survival with cell-based angiogenic gene therapy. Ann Thorac Surg. 2005; 80:1779-1786.
7. Terrovitis J V, Smith RR, Marbán E. Assessment and optimization of cell engraftment after transplantation into the heart. Circ Res. 2010; 106:479-494.
8. Bonios M, Terrovitis J, Chang CY, Engles JM, Higuchi T, Lautamäki R, Yu J, Fox J, Pomper M, Wahl RL, Tsui BM, O'Rourke B, Bengel FM, Marbán E, Abraham MR. Myocardial substrate and route of administration determine acute cardiac retention and lung biodistribution of cardiosphere-derived cells. J Nucl Cardiol. 2011; 18:443-450.
9. Stastna M, Van Eyk JE. Investigating the secretome lessons about the cells that comprise the heart. Circ Cardiovasc Genet. 2012; 5:08-018.
10. Kowal J, Tkach M, Théry C. Biogenesis and secretion of exosomes Introduction: the discovery of exosomes. Curr Opin Cell Biol. 2014; 29:116-125.
11. Valadi H, Ekström K, Bossios A, Sjöstrand M, Lee JJ, Lötvall JO. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol. 2007; 9:654-659.
12. Simons M, Raposo G. Exosomes - vesicular carriers for intercellular communication. Curr Opin Cell Biol. 2009; 21:575-581.
13. Mittelbrunn M, Gutiérrez-Vázquez C, Villarroya-Beltri C, González S, Sánchez-Cabo F, González Má, Bernad A, Sánchez-Madrid F. Unidirectional transfer of microRNA-loaded exosomes from T cells to antigen-presenting cells. Nat Commun. 2011; 2:282.
14. Lugini L, Cecchetti S, Huber V, Luciani F, Macchia G, Spadaro F, Paris L, Abalsamo L, Colone M, Molinari A, Podo F, Rivoltini L, Ramoni C, Fais S. Immune Surveillance Properties of Human NK Cell-Derived Exosomes. J Immunol. 2012; 189:2833-2842.
15. Yellon DM, Davidson SM. Exosomes: nanoparticles involved in cardioprotection? Circ Res. 2014; 114:325-332.
16. Vyas N, Dhawan J. Exosomes: mobile platforms for targeted and synergistic signaling across cell boundaries. Cell Mol Life Sci. 2017; 74:1567-1576.
17. Gray WD, French KM, Ghosh-Choudhary S, Maxwell JT, Brown ME, Platt MO, Searles CD, Davis ME. Identification of therapeutic covariant microRNA clusters in hypoxia-treated cardiac progenitor cell exosomes using systems biology. Circ Res. 2015; 116:255-263.
18. Ibrahim AGE, Cheng K, Marbán E. Exosomes as critical agents of cardiac regeneration triggered by cell therapy. Stem Cell Reports. 2014; 2:606-619.
19. Chen L, Wang Y, Pan Y, Zhang L, Shen C, Qin G, Ashraf M, Weintraub N, Ma G, Tang Y. Cardiac progenitor-derived exosomes protect ischemic myocardium from acute ischemia/reperfusion injury. Biochem Biophys Res Commun. 2013; 431:566-571.
20. Gallet R, Dawkins J, Valle J, Simsolo E, de Couto G, Middleton R, Tseliou E, Luthringer D, Kreke M, Smith RR, Marbán L, Ghaleh B, Marbán E. Exosomes secreted by cardiosphere-derived cells reduce scarring, attenuate adverse remodelling, and improve function in acute and chronic porcine myocardial infarction. Eur Heart J. 2016; 38:201-211.
21. Sherman W, Martens TP, Viles-Gonzalez JF, Siminiak T. Catheter-based delivery of cells to the heart. Nat Clin Pract Cardiovasc Med. 2006; 3 Suppl 1:S57-64.
22. Takahashi Y, Nishikawa M, Shinotsuka H, Matsui Y, Ohara S, Imai T, Takakura Y. Visualization and in vivo tracking of the exosomes of murine melanoma B16-BL6 cells in mice after intravenous injection. J Biotechnol. 2013; 165:77-84.
23. Bala S, Csak T, Momen-Heravi F, Lippai D, Kodys K, Catalano D, Satishchandran A, Ambros V, Szabo G. Biodistribution and function of extracellular miRNA-155 in mice. Sci Rep. 2015; 5:10721.
24. Tseliou E, Fouad J, Reich H, Slipczuk L, Couto G de, Aminzadeh M, Middleton R, Valle J, Weixin L, Marbán E. Exosomes from cardiac stem cells amplify their own bioactivity by converting fibroblasts to therapeutic cells. J Am Coll Cardiol. 2015; 66:599-11.
25. Vandergriff AC, de Andrade JBM, Tang J, Hensley MT, Piedrahita JA, Caranasos TG, Cheng K. Intravenous Cardiac Stem Cell-Derived Exosomes Ameliorate Cardiac Dysfunction in Doxorubicin Induced Dilated Cardiomyopathy. Stem Cells Int. 2015:960926.
26. Kanki S, Jaalouk DE, Lee S, Yu AYC, Gannon J, Lee RT. Identification of targeting peptides for ischemic myocardium by in vivo phage display. J Mol Cell Cardiol. 2011; 50:841-848.
27. Won YW, McGinn AN, Lee M, Bull DA, Kim SW. Targeted gene delivery to ischemic myocardium by homing peptide-guided polymeric carrier. Mol Pharm. 2013; 10:378-385.
28. Cappione A, Gutierrez S, Mabuchi M, Smith J, Strug I, Nadler T. A Centrifugal Ultrafiltration-Based Method for Enrichment of Microvesicles. Danvers, MA; 2014.
29. Shtam TA, Kovalev RA, Varfolomeeva EY, Makarov EM, Kil Y V, Filatov M V. Exosomes are natural carriers of exogenous siRNA to human cells in vitro. Cell Commun Signal. 2013; 11.
30. Théry C, Aled C, Sebastian A, Graça R. Isolation and Characterization of Exosomes from Cell Culture Supernatants. Curr Protoc Cell Biol. 2006; 3:1-29.
31. Kajimoto T, Okada T, Miya S, Zhang L, Nakamura S. Ongoing activation of sphingosine 1-phosphate receptors mediates maturation of exosomal multivesicular endosomes. Nat Commun. 2013; 4:2712.
32. Preibisch S, Saalfeld S, Tomancak P. Globally optimal stitching of tiled 3D microscopic image acquisitions. Bioinformatics. 2009; 25:1463-1465.
33. Vandergriff AC, Hensley MT, Cheng K. Isolation and Cryopreservation of Neonatal Rat Cardiomyocytes. J Vis Exp. 2015:1-7.
34. Vandergriff AC, Hensley MT, Cheng K. Cryopreservation of Neonatal Cardiomyocytes. Methods Mol Biol. 2015; 1299:153-160.
35. Lai RC, Yeo RWY, Tan KH, Lim SK. Exosomes for drug delivery - a novel application for the mesenchymal stem cell. Biotechnol Adv. 2013; 31:543-551.
36. Pan BT, Johnstone RM. Fate of the transferrin receptor during maturation of sheep reticulocytes in vitro: Selective externalization of the receptor. Cell. 1983; 33:967-978.
37. Harding C, Stahl P. Transferrin recycling in reticulocytes: pH and iron are important determinants of ligand binding and processing. Biochem Biophys Res Commun. 1983; 113:650-658.
38. Pan B-T, Teng K, Wu C, Adam M, Johnstone RM. Electron microscopic evidence for externalization of the transferrin receptor in vesicular form in sheep reticulocytes. J Cell Biol. 1985; 101:942-948.
39. Johnstone RM. Revisiting the road to the discovery of exosomes. Blood Cells, Mol Dis. 2005; 34:214-219.
40. Harding C V., Heuser JE, Stahl PD. Exosomes: Looking back three decades and into the future. J Cell Biol. 2013; 200:367-371.
41. Barile L, Lionetti V, Cervio E, Matteucci M, Gherghiceanu M, Popescu LM, Torre T, Siclari F, Moccetti T, Vassalli G. Extracellular vesicles from human cardiac progenitor cells inhibit cardiomyocyte apoptosis and improve cardiac function after myocardial infarction. Cardiovasc Res. 2014; 103:530-541.
42. Zhu H, Fan G-C. Extracellular/circulating microRNAs and their potential role in cardiovascular disease. Am J Cardiovasc Dis. 2011; 1:138-149.
43. Eulalio A, Mano M, Ferro MD, Zentilin L, Sinagra G, Zacchigna S, Giacca M. Functional screening identifies miRNAs inducing cardiac regeneration. Nature. 2012; 492:376-381.
44. Wang X, Ha T, Liu L, Zou J, Zhang X, Kalbfleisch J, Gao X, Williams D, Li C. Increased expression of microRNA-146a decreases myocardial ischaemia/reperfusion injury. Cardiovasc Res. 2013; 97:432-442.
45. Palomer X, Capdevila-Busquets E, Botteri G, Davidson MM, Rodríguez C, Martínez-González J, Vidal F, Barroso E, Chan TO, Feldman AM, Vázquez-Carrera M. miR-146a targets Fos expression in human cardiac cells. Dis Model Mech. 2015; 8:1081-1091.
46. Wang J, Liew OW, Richards AM, Chen YT. Overview of microRNAs in cardiac hypertrophy, fibrosis, and apoptosis. Int J Mol Sci. 2016; 17:1-21.
47. Sayed D, He M, Hong C, Gao S, Rane S, Yang Z, Abdellatif M. MicroRNA-21 is a downstream effector of AKT that mediates its antiapoptotic effects via suppression of fas ligand. J Biol Chem. 2010; 285:20281-20290.
48. Tu Y, Wan L, Fan Y, Wang K, Bu L, Huang T, Cheng Z, Shen B. Ischemic Postconditioning-Mediated miRNA-21 Protects against Cardiac ischemia/reperfusion Injury via PTEN/Akt Pathway. PLoS One. 2013; 8.
49. Huang W, Tian SS, Hang PZ, Sun C, Guo J, Du ZM. Combination of microRNA-21 and microRNA-146a Attenuates Cardiac Dysfunction and Apoptosis During Acute Myocardial Infarction in Mice. Mol Ther Acids. 2016; 5:e296.
50. Kasinski a L, Kelnar K, Stahlhut C, Orellana E, Zhao J, Shimer E, Dysart S, Chen X, Bader AG, Slack FJ. A combinatorial microRNA therapeutics approach to suppressing non-small cell lung cancer. Oncogene. 2014; 34:1-9.
51. Bartel DP. MicroRNAs: Target Recognition and Regulatory Functions. Cell. 2009; 136:215-233.
52. Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell. 2005; 120:15-20.
53. Lewis BP, Shih I-H, Jones-Rhoades MW, Bartel DP, Burge CB. Prediction of Mammalian MicroRNA Targets. Cell. 2003; 115:787-798.
54. Farh KK-H, Grimson A, Jan C, Lewis BP, Johnston WK, Lim LP, Burge CB, Bartel DP. The Widespread Impact of Mammalian MicroRNAs on mRNA Repression and Evolution. Science. 2005; 310:1817-1822.
55. Grimson A, Farh KKH, Johnston WK, Garrett-Engele P, Lim LP, Bartel DP. MicroRNA Targeting Specificity in Mammals: Determinants beyond Seed Pairing. Mol Cell. 2007; 27:91-105.
56. Mazière P, Enright AJ. Prediction of microRNA targets. Drug Discov Today. 2007; 12:452-458.
57. Dong CG, Wu WKK, Feng SY, Wang XJ, Shao JF, Qiao J. Co-inhibition of microRNA-10b and microRNA-21 exerts synergistic inhibition on the proliferation and invasion of human glioma cells. Int J Oncol. 2012; 41:1005-1012.
58. Noguchi S, Yasui Y, Iwasaki J, Kumazaki M, Yamada N, Naito S, Akao Y. Replacement treatment with microRNA-143 and -145 induces synergistic inhibition of the growth of human bladder cancer cells by regulating PI3K/Akt and MAPK signaling pathways. Cancer Lett. 2013; 328:353-361.
59. Pisano F, Altomare C, Cervio E, Barile L, Rocchetti M, Ciuffreda MC, Malpasso G, Copes F, Mura M, Danieli P, Viarengo G, Zaza A, Gnecchi M. Combination of miRNA499 and miRNA133 exerts a synergic effect on cardiac differentiation. Stem Cells. 2015; 33:1187-1199.
60. Smyth T, Kullberg M, Malik N, Smith-Jones P, Graner MW, Anchordoquy TJ. Biodistribution and delivery efficiency of unmodified tumor-derived exosomes. J Control Release. 2015; 199:145-155.
61. Yang T, Choi M-K, Cui F-D, Kim JS, Chung S-J, Shim C-K, Kim D-D. Preparation and evaluation of paclitaxel-loaded PEGylated immunoliposome. J Control Release. 2007; 120:169-177.
62. Kang DIL, Lee S, Lee JT, Sung BJ, Yoon J-Y, Kim J-K, Chung J, Lim S-J. Preparation and in vitro evaluation of anti-VCAM-1-Fab'-conjugated liposomes for the targeted delivery of the poorly water-soluble drug celecoxib. J Microencapsul. 2011; 28:220-227.
63. She W, Li N, Luo K, Guo C, Wang G, Geng Y, Gu Z. Dendronized heparin-doxorubicin conjugate based nanoparticle as pH-responsive drug delivery system for cancer therapy. Biomaterials. 2013; 34:2252-2264.
64. Klibanov AL, Khaw B-A, Nossiff N, O'Donnell SM, Huang L, Slinkin MA, Torchilin VP. Targeting of macromolecular carriers and liposomes by antibodies to myosin heavy chain. Am J Physiol. 1991; 261:60-65.
65. Khaw B-A, Torchilin V, Vural I, Narula J. Plug and seal: Prevention of hypoxic cardiocyte death by sealing membrane lesions with antimyosin-liposomes. Nat Med. 1995; 1:1195-1198.
66. Khaw B-A, Khudairi T. Dose-response to cytoskeletal-antigen specific immunoliposome therapy for preservation of myocardial viability and function in langendorff instrumented rat hearts. J Liposome Res. 2007; 17:63-77.
67. Khaw B-A, DaSilva J, Hartner WC. Cytoskeletal-antigen specific immunoliposome-targeted in vivo preservation of myocardial viability. J Control Release Off J Control Release Soc. 2007; 120:35-40.
68. Ko YT, Hartner WC, Kale A, Torchilin VP. Gene delivery into ischemic myocardium by double-targeted lipoplexes with anti-myosin antibody and TAT peptide. Gene Ther. 2009; 16:52-59.
69. Scott RC, Crabbe D, Krynska B, Ansari R, Kiani MF. Aiming for the heart: targeted delivery of drugs to diseased cardiac tissue. Expert Opin Drug Deliv. 2008; 5:459-470.
70. Dvir T, Bauer M, Schroeder A, Tsui JH, Anderson DG, Langer R, Liao R, Kohane DS. Nanoparticles for targeting the infarcted heart. Nano Lett. 2011; 11:4411-4414.
71. Zhang B, Green J V, Murthy SK, Radisic M. Label-free enrichment of functional cardiomyocytes using microfluidic deterministic lateral flow displacement. PLoS One. 2012; 7:e37619.
72. Nguyen MM, Carlini AS, Chien MP, Sonnenberg S, Luo C, Braden RL, Osborn KG, Li Y, Gianneschi NC, Christman KL. Enzyme-Responsive Nanoparticles for Targeted Accumulation and Prolonged Retention in Heart Tissue after Myocardial Infarction. Adv Mater. 2015; 27:5547-5552.
73. Kamps JA, Krenning G. Micromanaging cardiac regeneration: Targeted delivery of microRNAs for cardiac repair and regeneration. World J Cardiol. 2016; 8:163.
74. Weis SM. Vascular permeability in cardiovascular disease and cancer. Curr Opin Hematol. 2008; 15:243-249.
75. Liu M, Li M, Sun S, Li B, Du D, Sun J, Cao F, Li H, Jia F, Wang T, Chang N, Yu H, Wang Q, Peng H. The use of antibody modified liposomes loaded with AMO-1 to deliver oligonucleotides to ischemic myocardium for arrhythmia therapy. Biomaterials. 2014; 35:3697-3707.
76. Tang J, Su T, Huang K, Dinh PU, Wang Z, Vandergriff AC, Hensley MT, Cores J, Allen T, Li TS, Sproul E, Mihalko E, Lobo LJ, Ruterbories L, Lynch A, Brown AC, Caranasos TG, Shen D, Stouffer GA, Gu Z, Zhang J, Cheng K. Targeted repair of heart injury by stem cells fused with platelet nanovesicles. Nature Biomedical Engineering. 2018;2:17-26.
77. Tang J, Shen D, Caranasos TG, Wang Z, Allen TA, Vandergriff A, Hensley MT, Dinh PU, Cores J, Li TS, Zhang J, Kan Q, and Cheng K. Therapeutic microparticles functionalized with biomimetic cardiac stem cell membranes and secretome. Nature Communications. 2017; 8:13724.
78. Luo L, Tang J, Nishi K, Yan C, Dinh PU, Cores J, Kudo T, Zhang J, Li TS, Cheng K. Fabrication of synthetic mesenchymal stem cells for hear repair. Circulation Research. 2017; 120:1768-1775.
79. Kim H, Song KD, Kim HJ, Park WC, Kim J, Lee T, Shin DH, Kwak W, Kwon YJ, Sung S, Moon S, Lee KT, Kim N, Hong JK, Eo KY, et al. Exploring the genetic signature of body size in Yucatan miniature pig. PLoS One. 2015; 10:1-16.